# A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

> **NCT01022424** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 13 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease

## Interventions

- **DRUG:** OPC-41061

## Key facts

- **NCT ID:** NCT01022424
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022424, "A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01022424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*